Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Everest Medicines Announces Amended Agreement with Spero Therapeutics
Spero will assign relevant SPR206 patents to Everest Medicines in Greater China, South Korea and certain Southeast Asian countries
News provided by
Share this article
Share this article
SHANGHAI, Jan. 18, 2021 /PRNewswire/ Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that under an amended license agreement with Spero Therapeutics, the relevant patents for SPR206 will be assigned to Everest in Greater China, South Korea and certain Southeast Asian countries (the Territory ). The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory.